Across its top 20 institutional holders, SLS's holder base skews toward low-concentration, low-turnover investors on average (avg. concentration score 6/100, avg. turnover score 22/100).

Quarterly Activity

Recent Activity

+$231.1M

Total Buy Value

$40.4M

Total Sell Value

New buy60

Trim24

Add55

Sold out16

115

Net Buyers

Net Sellers

Smart Money Convergence

SLS does not currently have enough recent insider (Form 4) trading activity to compute a convergence signal against its 13F institutional flows.

13F data as of 2026-06-30 quarterly filings. Note: many large institutions file close to the 45-day post-quarter deadline, so early-quarter flow figures can shift substantially as more filings arrive.

Insider Trading (Form 4)

Form 144 Pre-Sale Notices

No Form 144 planned sale filings in the last 90 days

Beneficial Ownership (13D/13G)

No Schedule 13D/13G filings for this ticker

Material Events (8-K)

No Form 8-K filings for this ticker

CUSIP

81642T209

FAQ

Who are the top institutional investors holding SELLAS LIFE SCIENCES GROUP I (SLS)?

Major stakeholders currently include BlackRock, Inc. ($51.6M), Susquehanna International Group, LLP ($38.0M), State Street CORP ($35.5M). Based on the latest 13F filings, there are a total of 162 tracked investment funds and institutions maintaining positions in SLS.

What is the overall institutional sentiment toward SLS recently?

Institutional sentiment appears Bullish (Net Buying). During the most recent reporting quarter, the stock experienced a net inflow of $115.8M, driven by 115 managers accumulating shares while 40 reduced their exposure.

Which institutions have been selling or reducing their SLS positions?

In the latest period, 24 funds trimmed their holdings, and 16 managers completely exited their positions. The aggregate reported sell value was $40.4M.

Are there any notable investors adding SLS to their portfolios?

Yes, buying activity remains notable. 60 institutions opened new positions in {ticker}, and 55 existing holders added to their shares. The total reported buy value for the quarter amounted to $231.1M.